In the context of immunotherapy, synergistic effects of PD-1/PD-L1 checkpoint inhibitors and vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR) have been demonstrated, and combination therapy improves tumor response, as well as improves overall survival of gastric cancer patients60. The gene discussed is KDR; the disease is neoplasm.